Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENDO INTERNATIONAL PLC

(ENDP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Endo International Strikes Deal to Supply Vasostrict Vials Through Premier Program; Shares Gain

11/08/2021 | 12:41pm EST


© MT Newswires 2021
All news about ENDO INTERNATIONAL PLC
01/19MARKETSCREENER’S WORLD PRESS REVIEW : January 19, 2022
01/18Endo International Reaches Settlement With Florida Over Opioid Claims
MT
01/18Drugmaker Endo signs $65 million opioid settlement with Florida
RE
01/18Endo Reaches Agreement Intended to Settle Florida Governmental Opioid Cases and Claims
PR
01/17Paladin Labs Announces the Launch of Xydalba® (dalbavancin for injection) in Canada
AQ
01/13Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Review..
PR
01/13Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Review..
CI
01/11Endo Launches New Dupuytren's Contracture Campaign Featuring Real Patients, Watching Ed..
AQ
01/11ENDO INTERNATIONAL : at J.P. Morgan Healthcare Conference
PU
01/11ENDO INTERNATIONAL PLC : Regulation FD Disclosure (form 8-K)
AQ
More news
Analyst Recommendations on ENDO INTERNATIONAL PLC
More recommendations
Financials (USD)
Sales 2021 2 940 M - -
Net income 2021 10,2 M - -
Net Debt 2021 6 712 M - -
P/E ratio 2021 2,33x
Yield 2021 -
Capitalization 750 M 750 M -
EV / Sales 2021 2,54x
EV / Sales 2022 2,56x
Nbr of Employees 3 397
Free-Float -
Chart ENDO INTERNATIONAL PLC
Duration : Period :
Endo International plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENDO INTERNATIONAL PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 3,21 $
Average target price 6,17 $
Spread / Average Target 92,1%
EPS Revisions
Managers and Directors
Blaise A Coleman President, Chief Executive Officer & Director
Mark Bradley Chief Financial Officer & Executive Vice President
Mark G. Barberio Chairman
Ruth Thorpe Chief Information Officer
James Patrick Tursi Executive VP-Global Research & Development